Abstract Views: 327 |
PDF Views: 0
Authors
M. R. Vijayababu
Department of Endocrinology, Dr. ALM Post Graduate Institute of Basic Medical Sciences, University of Madras, Taramani Campus, Chennai 600 113, India
P. Kanagaraj
Department of Endocrinology, Dr. ALM Post Graduate Institute of Basic Medical Sciences, University of Madras, Taramani Campus, Chennai 600 113, India
A. Arunkumar
Department of Endocrinology, Dr. ALM Post Graduate Institute of Basic Medical Sciences, University of Madras, Taramani Campus, Chennai 600 113, India
Siva Dhanammal
Department of Endocrinology, Dr. ALM Post Graduate Institute of Basic Medical Sciences, University of Madras, Taramani Campus, Chennai 600 113, India
K. Balasubramanian
Department of Endocrinology, Dr. ALM Post Graduate Institute of Basic Medical Sciences, University of Madras, Taramani Campus, Chennai 600 113, India
N. Srinivasan
Department of Endocrinology, Dr. ALM Post Graduate Institute of Basic Medical Sciences, University of Madras, Taramani Campus, Chennai 600 113, India
M. M. Aruldhas
Department of Endocrinology, Dr. ALM Post Graduate Institute of Basic Medical Sciences, University of Madras, Taramani Campus, Chennai 600 113, India
J. Arunakaran
Department of Endocrinology, Dr. ALM Post Graduate Institute of Basic Medical Sciences, University of Madras, Taramani Campus, Chennai 600 113, India
Abstract
Recent estimates have placed prostate cancer as the most commonly diagnosed malignancy. It is the fourth most common cancer in men worldwide. Androgen dependent prostate cancer can responds to androgen ablative therapy. However, if the cell contains heterogeneous population of both androgen dependent and androgen independent, the androgen ablative therapy can only responds to androgen dependent cell population but not to independent cancer.
DOI:
https://doi.org/10.18519/jer%2F2003%2Fv7%2F98905